Consolidated Q2 FY27 revenue up 38%, profit after tax up 44% versus Q2 FY26

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionExceptional itemRelated-party transactionsResults View source PDF Explain this filing

HESTERBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.1%Reaction day

₹2319.20

prior close

₹2479.10

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 171sector+0.5%+2.6% vs sector

On the reaction day the stock moved 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

+0.0

15m

+0.2

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.1pendingpending+0.5+2.6

Next day

+2.3pendingpending+0.4+1.9

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q2 FY27 revenue rose 38% to INR 979.12 million from INR 709.69 million in Q2 FY26; profit after tax rose 44% to INR 206.31 million from INR 143.31 million. EBITDA margin rose to 37% from 33%; Q2 exceptional items were INR 4.19 million. H1 consolidated PAT was INR 1,173.63 million, including an INR 857.68 million gain from the Gates Foundation loan at Hester Africa. Board approved a USD 1 million unsecured loan to Hester Africa at 9%.

Likely market impact

Strong Q2 growth and wider margins support earnings, but much of H1 profit came from a one-time loan gain; the new subsidiary loan adds exposure.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹97.91 Cr	₹70.97 Cr	+38.0%
Operating profit	₹22.60 Cr	₹5.16 Cr	+338.2%
Profit after tax	₹20.63 Cr	₹14.33 Cr	+44.0%
EBITDA margin	33.8%	16.5%	+17.3 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.